臺灣博碩士論文加值系統

自工業革命至今，空氣汙染一直是人類關注的健康議題。過去的流行病學研究及動物實驗發現微粒空氣汙染和對呼吸系統及心血管系統的不良健康效應相關，如肺間質細胞發炎、氣喘、慢性阻塞性肺病 (COPD)、動脈硬化、缺血性心臟病、心律不整、心臟衰竭等。前人研究多鎖定特定細胞激素與組織，預期微粒空氣汙染暴露會造成這些細胞激素的上升以及組織的損傷。以核磁共振儀為基礎的代謝體學由另一個方向切入，以驗證已知生化指標、釐清可能的毒理機制、及尋找新的指標為目標，建立及比較生物體體內內生性代謝物的資訊。我們設計了一個亞慢性大氣微粒全身性呼吸暴露動物實驗，將32隻Sprague-Dawley大鼠隨機分為微粒空氣暴露組及乾淨空氣暴露組(控制組) 進行一天24小時，一週七天，為期十二週的微粒空氣汙染暴露。為校正個體差異，本研究將暴露前兩天設為基準點(baseline)，並於暴露後五天、七天、四週及十二週針對同一批老鼠(N=8/group/time-point)以連續採樣的方式採集血液及尿液進行以核磁共振儀為基礎的代謝體學研究，並於暴露後七天、四週及十二週犧牲(N=3/group/time-point)，進行血液學及肺泡灌洗液發炎反應分析。本研究採用主成份分析法(PCA)、部分最小平方判別分析法(PLS-DA)以及學生T檢定(Student’s t-test)進行代謝物辨認、資料分群檢測及半定量統計分析，以利後續針對PM可能的毒理機制的建構。
實驗過程中，PM2.5於暴露滿五天、七天、四週及十二週的平均質量濃度分別為20.86μg/m3、20.87μg/m3、19.30μg/m3、及13.73μg/m3。暴露後七天、四週及十二週實驗動物的血液學檢查、細胞計數及肺泡灌洗液發炎指標於兩組間均未呈現明顯差異。血清代謝體的PCA分析發現，四週及十二週的微粒空氣暴露組及控制組呈現分群之趨勢，在代謝物半定量分析的部分，若以暴露組和控制組相較，暴露七天微粒空氣在兩組中代謝物含量無顯著差異；五天時微粒組的血清在citrate, choline及creatine的量呈上升趨勢，四週時creatine、acetate與胺基酸valine、methionine、tyrosine呈上升趨勢，飽和、不飽和脂肪鏈、低密度脂蛋白及極低密
度脂蛋白成下降趨勢；而暴露十二週時choline、phosphocholine、胺基酸valine、alanine、glutamine、methionine、tyrosine、能量代謝相關的acetoacetate、pyruvate、citrate、creatine、glucose成下降趨勢，飽和脂肪鏈、formate、低密度脂蛋白及極低密度脂蛋白則呈上升趨勢。以上PCA及半定量分析結果顯示亞慢性PM2.5暴露和生物體內代謝物表現之擾動有相關，而這些代謝物的擾動表現於能量代謝、脂質代謝及細胞膜恆定等層面。
本研究藉由核磁共振譜的代謝體學，分析健康SD大鼠暴露微粒空氣汙染後體內代謝物組成的改變，藉以評估微粒空氣汙染對生物體造成的危害及可能機制，以幫助未來生物標記之發展。

Both epidemiological and animal studies had indicated clear association between adverse health effects of the pulmonary and cardiovascular system with particulate matter (PM) air pollution. These studies approached the outcomes specifically, suggesting exposure of PM lead to elevation of cytokines and tissue lesions. The use of NMR-based metabolomics provided a global profiling of the endogenous metabolites in our body, aiming at the verification of known biomarkers, clarification of possible toxicological mechanisms, and finding of novel markers.
A 12-week whole body ambient PM inhalation exposure design was conducted with 16 male SD rats randomly divided into the ambient air exposure group and the filtered-air group for a 24 hr/day, 7 days/week exposure. Serial sampling of serum was held for adjustment of individual variation at time points of -2 days(baseline), 7 days, 4 weeks, and 12 weeks of exposure for NMR-based metabolomic analysis. Another 16 male SD rats in the same age were also randomly divided into the two groups and were sacrificed for hematological analysis, cell differential and inflammatory biomarker analysis of bronchial alveolar lavage fluid (BALF) at time points of 5 days, 7 days, 4 weeks, and 12 weeks of exposure (N=3/group/time-points). Principal component analysis (PCA), partial least squares discriminant analysis (PLS-DA) and Student’s t-test were employed to identifying critical metabolites for the clarification of possible
mechanisms of toxicological effects of PM in the body.
The estimated average mass concentration of PM2.5 at 7 days, 4 weeks, and 12 weeks were 20.86μg/m3, 20.87μg/m3, 19.30μg/m3, 13.73μg/m3, respectively. PCA scores plot from the analysis of NMR spectra of serum showed a trend separation and clustering according to exposure and control groups at both 4 and 12 weeks of exposure. Compared to the control group, decrease levels of the -CH2 of LDL and VLDL and increase level of creatine, citrate and choline were found at 5 days of exposure; saturated and unsaturated fatty acid chains, and increase levels of valine, acetate, methionine, tyrosine and creatine were found at 4 weeks of exposure, while valine, alanine, acetoacetate, pyruvate, glutamine, citrate, methionine, choline, phosphocholine, creatine, glucose and tyrosine were found decreased and increase level of –CH2 of LDL and VLDL, saturated fatty acid chain and formate were found at 12 week of exposure.
Our findings suggested that sub-chronic inhalation of PM at ambient level might have an association with the perturbation of TCA cycle, energy metabolism, amino acid and lipid metabolism, and disruption of energy production and the increase of ROS production.

口試委員會審定書…………………………………………………….…..I
誌謝……………………………………………………………………. …II
中文摘要……………………………………………………………….....III
Abstract ……………………………………………………………………V
Contents …………………………………………………………………VII
List of Tables..…………………………………………………………….IX
List of Figures……………………………………………………………...X

Chapter 1 Introduction
1.1 Research Background………………………………………………1
1.2 Objectives…………………………………………………………..4

Chapter 2 Literature review
2.1 Particulate matter and Respiratory Diseases……………………….5
2.2 Particulate Matter and Cardiovascular Diseases…………………...6
2.3 Metabolomics………………………………………………………8
2.3.1 NMR spectroscopy as a tool of reaching Metabolomics……..10
2.3.2 Metabolomics and particulate matter-related diseases………. 11
2.4 Exposure Routes…………………………………………………..12

Chapter 3 Materials and Methods
3.1 Animals and Animal Care…………………………………………15
3.2 Exposures to Ambient Particulate Matter…………………………15
3.2.1 Study Design…………………………………………………15
3.2.2 The TAPES…………………………………………………...17
3.2.3 Exposure Monitoring…………………………………………17
3.3 Metabolomic Parameters………………………………………….18
3.3.1 Sample Collection and Preparation…………………………..18
3.3.2 1H NMR Spectral Acquisition………………………………..19
3.3.3 Spectral Processing and Spectral Data Analysis…………….. 19
3.3.4 Metabolite Identification……………………………………..21
3.4 Measurement of biomarkers………………………………………21
3.4.1 Collection and preparation of Samples……………………… 21
3.4.2 Measurement of Inflammatory Factors and Blood Analysis…22
3.5 Statistical Analysis……………………………………………….. 22

Chapter 4 Results
4.1 Exposure Data……………………………………………………. 23
4.2 Body weight change of experimental animals…………………….23
4.3 Hematological analysis……………………………………………24
4.4 Inflammatory Factors……………………………………………..24
4.5 1H NMR Spectroscopy of Rat Serum……………………………..24
4.5.1 Metabolic Response to Acute PM Inhalation Exposure……...26
4.5.2 Metabolic Response to Chronic PM Inhalation Exposure…...26

Chapter 5 Discussion…………………………………………………..28
Chapter 6 Conclusion………………………………………………….35
Reference…………………………………………………………………36

1.Brook RD, Rajagopalan S, Pope CA, 3rd, Brook JR, Bhatnagar A, Diez-Roux AV, Holguin F, Hong Y, Luepker RV, Mittleman MA, et al: Particulate matter air pollution and cardiovascular disease: An update to the scientific statement from the American Heart Association. Circulation 2010, 121:2331-2378.
2.Dockery DW, Pope CA, 3rd, Xu X, Spengler JD, Ware JH, Fay ME, Ferris BG, Jr., Speizer FE: An association between air pollution and mortality in six U.S. cities. N Engl J Med 1993, 329:1753-1759.
3.Pope CA, 3rd, Thun MJ, Namboodiri MM, Dockery DW, Evans JS, Speizer FE, Heath CW, Jr.: Particulate air pollution as a predictor of mortality in a prospective study of U.S. adults. Am J Respir Crit Care Med 1995, 151:669-674.
4.Pope CA, 3rd, Burnett RT, Thun MJ, Calle EE, Krewski D, Ito K, Thurston GD: Lung cancer, cardiopulmonary mortality, and long-term exposure to fine particulate air pollution. JAMA 2002, 287:1132-1141.
5.Hsieh YL, Yang YH, Wu TN, Yang CY: Air pollution and hospital admissions for myocardial infarction in a subtropical city: Taipei, Taiwan. J Toxicol Environ Health A 2010, 73:757-765.
6.Tsai SS, Chiu HF, Wu TN, Yang CY: Air pollution and emergency room visits for cardiac arrhythmia in a subtropical city: Taipei, Taiwan. Inhal Toxicol 2009, 21:1113-1118.
7.Bell ML, Levy JK, Lin Z: The effect of sandstorms and air pollution on cause-specific hospital admissions in Taipei, Taiwan. Occup Environ Med 2008, 65:104-111.
8.Ling SH, van Eeden SF: Particulate matter air pollution exposure: role in the development and exacerbation of chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis 2009, 4:233-243.
9.Gauderman WJ, Avol E, Gilliland F, Vora H, Thomas D, Berhane K, McConnell R, Kuenzli N, Lurmann F, Rappaport E, et al: The effect of air pollution on lung development from 10 to 18 years of age. N Engl J Med 2004, 351:1057-1067.
10.Clark NA, Demers PA, Karr CJ, Koehoorn M, Lencar C, Tamburic L, Brauer M: Effect of early life exposure to air pollution on development of childhood asthma. Environ Health Perspect 2010, 118:284-290.
11.Gehring U, Wijga AH, Brauer M, Fischer P, de Jongste JC, Kerkhof M, Oldenwening M, Smit HA, Brunekreef B: Traffic-related air pollution and the development of asthma and allergies during the first 8 years of life. Am J Respir Crit Care Med 2010, 181:596-603.
12.Sin DD, Wu L, Man SF: The relationship between reduced lung function and cardiovascular mortality: a population-based study and a systematic review of the literature. Chest 2005, 127:1952-1959.
13.Andersen ZJ, Hvidberg M, Jensen SS, Ketzel M, Loft S, Sorensen M, Tjonneland A, Overvad K, Raaschou-Nielsen O: Chronic obstructive pulmonary disease and long-term exposure to traffic-related air pollution: a cohort study. Am J Respir Crit Care Med 2011, 183:455-461.
14.Franchini M, Mannucci PM: Particulate air pollution and cardiovascular risk: short-term and long-term effects. Semin Thromb Hemost 2009, 35:665-670.
15.Ghio AJ, Kim C, Devlin RB: Concentrated ambient air particles induce mild pulmonary inflammation in healthy human volunteers. Am J Respir Crit Care Med 2000, 162:981-988.
16.Gurgueira SA, Lawrence J, Coull B, Murthy GG, Gonzalez-Flecha B: Rapid increases in the steady-state concentration of reactive oxygen species in the lungs and heart after particulate air pollution inhalation. Environ Health Perspect 2002, 110:749-755.
17.Peters A, Frohlich M, Doring A, Immervoll T, Wichmann HE, Hutchinson WL, Pepys MB, Koenig W: Particulate air pollution is associated with an acute phase response in men; results from the MONICA-Augsburg Study. Eur Heart J 2001, 22:1198-1204.
18.Sharman JE, Coombes JS, Geraghty DP, Fraser DI: Exposure to automotive pollution increases plasma susceptibility to oxidation. Arch Environ Health 2002, 57:536-540.
19.Gold DR, Litonjua A, Schwartz J, Lovett E, Larson A, Nearing B, Allen G, Verrier M, Cherry R, Verrier R: Ambient pollution and heart rate variability. Circulation 2000, 101:1267-1273.
20.Pope CA, 3rd, Verrier RL, Lovett EG, Larson AC, Raizenne ME, Kanner RE, Schwartz J, Villegas GM, Gold DR, Dockery DW: Heart rate variability associated with particulate air pollution. Am Heart J 1999, 138:890-899.
21.Park SK, O''Neill MS, Vokonas PS, Sparrow D, Schwartz J: Effects of air pollution on heart rate variability: the VA normative aging study. Environ Health Perspect 2005, 113:304-309.
22.O''Toole TE, Conklin DJ, Bhatnagar A: Environmental risk factors for heart disease. Rev Environ Health 2008, 23:167-202.
23.Simkhovich BZ, Kleinman MT, Kloner RA: Air pollution and cardiovascular injury epidemiology, toxicology, and mechanisms. Journal of the American College of Cardiology 2008, 52:719-726.
24.Zhao J, Xie Y, Qian X, Jiang R, Song W: Acute effects of fine particles on cardiovascular system: differences between the spontaneously hypertensive rats and wistar kyoto rats. Toxicol Lett 2010, 193:50-60.
25.Xia T, Kovochich M, Nel AE: Impairment of mitochondrial function by particulate matter (PM) and their toxic components: implications for PM-induced cardiovascular and lung disease. Front Biosci 2007, 12:1238-1246.
26.Xu X, Liu C, Xu Z, Tzan K, Zhong M, Wang A, Lippmann M, Chen LC, Rajagopalan S, Sun Q: Long-term exposure to ambient fine particulate pollution induces insulin resistance and mitochondrial alteration in adipose tissue. Toxicol Sci 2011, 124:88-98.
27.Hou L, Zhu ZZ, Zhang X, Nordio F, Bonzini M, Schwartz J, Hoxha M, Dioni L, Marinelli B, Pegoraro V, et al: Airborne particulate matter and mitochondrial damage: a cross-sectional study. Environ Health 2010, 9:48.
28.Bino RJ, Hall RD, Fiehn O, Kopka J, Saito K, Draper J, Nikolau BJ, Mendes P, Roessner-Tunali U, Beale MH, et al: Potential of metabolomics as a functional genomics tool. Trends Plant Sci 2004, 9:418-425.
29.Dunn WB, Bailey NJ, Johnson HE: Measuring the metabolome: current analytical technologies. Analyst 2005, 130:606-625.
30.Feng J, Li X, Pei F, Chen X, Li S, Nie Y: 1H NMR analysis for metabolites in serum and urine from rats administrated chronically with La(NO3)3. Anal Biochem 2002, 301:1-7.
31.German JB, Hammock BD, Watkins SM: Metabolomics: building on a century of biochemistry to guide human health. Metabolomics 2005, 1:3-9.
32.Goodacre R, Vaidyanathan S, Dunn WB, Harrigan GG, Kell DB: Metabolomics by numbers: acquiring and understanding global metabolite data. Trends Biotechnol 2004, 22:245-252.
33.Rochfort S: Metabolomics reviewed: a new "omics" platform technology for systems biology and implications for natural products research. J Nat Prod 2005, 68:1813-1820.
34.Smolinska A, Blanchet L, Buydens LM, Wijmenga SS: NMR and pattern recognition methods in metabolomics: from data acquisition to biomarker discovery: a review. Anal Chim Acta 2012, 750:82-97.
35.Dunn WB, Broadhurst DI, Atherton HJ, Goodacre R, Griffin JL: Systems level studies of mammalian metabolomes: the roles of mass spectrometry and nuclear magnetic resonance spectroscopy. Chem Soc Rev 2011, 40:387-426.
36.Fiehn O: Metabolomics--the link between genotypes and phenotypes. Plant Mol Biol 2002, 48:155-171.
37.Mamas M, Dunn WB, Neyses L, Goodacre R: The role of metabolites and metabolomics in clinically applicable biomarkers of disease. Arch Toxicol 2011, 85:5-17.
38.Quinn MT, Parthasarathy S, Fong LG, Steinberg D: Oxidatively modified low density lipoproteins: a potential role in recruitment and retention of monocyte/macrophages during atherogenesis. Proc Natl Acad Sci U S A 1987, 84:2995-2998.
39.Kuller L, Arnold A, Tracy R, Otvos J, Burke G, Psaty B, Siscovick D, Freedman DS, Kronmal R: Nuclear magnetic resonance spectroscopy of lipoproteins and risk of coronary heart disease in the cardiovascular health study. Arterioscler Thromb Vasc Biol 2002, 22:1175-1180.
40.Jung J, Kim SH, Lee HS, Choi GS, Jung YS, Ryu DH, Park HS, Hwang GS: Serum metabolomics reveals pathways and biomarkers associated with asthma pathogenesis. Clin Exp Allergy 2013, 43:425-433.
41.Liao Peiqiu WL, Wu Huifeng, Li Weisheng, Wu Yijie, Li Xiaojing, Ni Jiazuan, Pei Fenkui: Biochemical effects of gadolinium chloride in rats liver and kidney studied by 1H NMR metabolomics. Journal of rare earths 2008, 27.
42.Pan Z, Raftery D: Comparing and combining NMR spectroscopy and mass spectrometry in metabolomics. Anal Bioanal Chem 2007, 387:525-527.
43.Beckonert O, Keun HC, Ebbels TM, Bundy J, Holmes E, Lindon JC, Nicholson JK: Metabolic profiling, metabolomic and metabonomic procedures for NMR spectroscopy of urine, plasma, serum and tissue extracts. Nat Protoc 2007, 2:2692-2703.
44.Howard BV: Acetate as a Carbon Source for Lipid-Synthesis in Cultured-Cells. Biochimica Et Biophysica Acta 1977, 488:145-151.
45.Goldberg RP, Brunengraber H: Contributions of cytosolic and mitochondrial acetyl-CoA syntheses to the activation of lipogenic acetate in rat liver. Adv Exp Med Biol 1980, 132:413-418.
46.Goodnight SH, Jr., Harris WS, Connor WE, Illingworth DR: Polyunsaturated fatty acids, hyperlipidemia, and thrombosis. Arteriosclerosis 1982, 2:87-113.
47.Ross R: Cell biology of atherosclerosis. Annu Rev Physiol 1995, 57:791-804.
48.Mora S, Otvos JD, Rifai N, Rosenson RS, Buring JE, Ridker PM: Lipoprotein particle profiles by nuclear magnetic resonance compared with standard lipids and apolipoproteins in predicting incident cardiovascular disease in women. Circulation 2009, 119:931-939.
49.Mora S, Otvos JD, Rosenson RS, Pradhan A, Buring JE, Ridker PM: Lipoprotein particle size and concentration by nuclear magnetic resonance and incident type 2 diabetes in women. Diabetes 2010, 59:1153-1160.
50.Treichel JL, Henry MM, Skumatz CM, Eells JT, Burke JM: Formate, the toxic metabolite of methanol, in cultured ocular cells. Neurotoxicology 2003, 24:825-834.
51.Nicholls P: Formate as an inhibitor of cytochrome c oxidase. Biochem Biophys Res Commun 1975, 67:610-616.
52.Du L, Su Y, Sun D, Zhu W, Wang J, Zhuang X, Zhou S, Lu Y: Formic acid induces Yca1p-independent apoptosis-like cell death in the yeast Saccharomyces cerevisiae. FEMS Yeast Res 2008, 8:531-539.
53.Lee HC, Wei YH: Mitochondrial biogenesis and mitochondrial DNA maintenance of mammalian cells under oxidative stress. Int J Biochem Cell Biol 2005, 37:822-834.
54.Reed DJ, Orrenius S: The role of methionine in glutathione biosynthesis by isolated hepatocytes. Biochem Biophys Res Commun 1977, 77:1257-1264.
55.Amores-Sanchez MI, Medina MA: Glutamine, as a precursor of glutathione, and oxidative stress. Molecular Genetics and Metabolism 1999, 67:100-105.